AstraZeneca plc vs Ishares Msci Thailand Etf — how do they compare? AstraZeneca plc trades at $159.37 (market cap $250.84B), while Ishares Msci Thailand Etf trades at $72.91. The key difference: AstraZeneca plc pays a 1.97% dividend while Ishares Msci Thailand Etf pays none, and Ishares Msci Thailand Etf is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | THD | |
|---|---|---|
Market Cap | $250.84B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $209.48 | $75.05 |
52-Week Low | $147.06 | $56.41 |
Enterprise Value | $278.12B | — |
Dividend Yield | 1.97% | — |
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.42, up 0.22% today, amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth to $58.74B in 2025 and net income of $10.23B, supported by a P/E of 24.16 and robust profitability margins. Recent news highlights potential talks with Bristol Myers Squibb, though a senior source denied ongoing discussions (Reuters, 2026-08-05).
The outlook is mixed: solid earnings beats and a 47.5% analyst buy rating support upside, but technical weakness and merger uncertainty pose near-term risks. Long-term growth hinges on execution amid competitive and regulatory pressures, with the stock offering value if merger rumors subside and fundamentals prevail.
THD trades at $73.63, up 1.03% for the day, with technical indicators showing a bullish trend from moving averages but neutral oscillators. The stock has shown strong performance, driven by exposure to AI hardware plays like Delta Electronics, contributing to its 38% total returns over the past year, as noted by Seeking Alpha on July 9, 2026. A dividend of $1.71 is scheduled for June 2026, adding income potential.
Outlook remains positive due to AI-driven growth, but risks include vulnerability to semiconductor sector volatility and foreign capital outflows from Asian equities. Investors should weigh the bullish technicals against macroeconomic uncertainties in the region for balanced exposure.
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →THD is a country-specific ETF that tracks the performance of the Thai equity market. It provides broad exposure to Thailand's economy across sectors like electronics, energy, and financials, with top holdings such as Delta Electronics.
Read more on THD →